Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

C1425000

Chloramphenicol sodium succinate

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Chloramphenicol succinate sodium salt, Chloramphenicol α-succinate

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór liniowy:
C15H15Cl2N2O8Na
Numer CAS:
982-57-0
Masa cząsteczkowa:
445.18
Numer MDL:
MFCD00079025
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329774883
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

chloramphenicol

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

ciąg SMILES

[Na].O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)N(=O)=O

InChI

1S/C15H16Cl2N2O8.Na.H/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26;;/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21);;/t10-,13-;;/m1../s1

Klucz InChI

RJOAHMNSYANTPN-OWVUFADGSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Chloramphenicol sodium succinate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.

produkt powiązany

Numer produktu
Opis
Cennik

C1200000

Chloramphenicol, European Pharmacopoeia (EP) Reference Standard

C1400000

Chloramphenicol palmitate isomer, European Pharmacopoeia (EP) Reference Standard

C1300000

Chloramphenicol dipalmitate, European Pharmacopoeia (EP) Reference Standard

C1350000

Chloramphenicol disodium disuccinate, European Pharmacopoeia (EP) Reference Standard

PHR1412

Chloramphenicol, Pharmaceutical Secondary Standard; Certified Reference Material

1107004

Chloramphenicol, United States Pharmacopeia (USP) Reference Standard

1107300

Chloramphenicol palmitate, United States Pharmacopeia (USP) Reference Standard

1107401

Chloramphenicol palmitate nonpolymorph A, United States Pharmacopeia (USP) Reference Standard

1107503

Chloramphenicol palmitate polymorph A, United States Pharmacopeia (USP) Reference Standard

BP854

Chloramphenicol, British Pharmacopoeia (BP) Reference Standard

BP1061

Chloramphenicol sodium succinate, British Pharmacopoeia (BP) Reference Standard

BP417

2-Amino-1-(4-nitrophenyl)propane-1,3-diol, British Pharmacopoeia (BP) Reference Standard

Piktogramy

Health hazardExclamation mark
GHS08,GHS07

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

H302,H351

Zwroty wskazujące środki ostrożności

P201 - P301 + P312 + P330 - P308 + P313

Klasyfikacja zagrożeń

Acute Tox. 4 Oral - Carc. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

J A Turton et al.
International journal of experimental pathology, 83(5), 225-238 (2003-03-19)
In man, chloramphenicol (CAP), induces two major haemotoxic effects. First, a reversible, dose-related reticulocytopenia and anaemia developing during treatment. Second, a non-dose-related aplastic anaemia (AA), developing weeks after treatment, is often irreversible and fatal. In previous studies, we developed a
M F Festing et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 39(4), 375-383 (2001-04-11)
Much toxicological research continues to be done using genetically undefined "outbred" stocks of mice and rats, although the case for using isogenic strains has been made repeatedly in the literature over a period of more than two decades. Also, very
C S Ambekar et al.
European journal of clinical pharmacology, 56(5), 405-409 (2000-09-29)
The metabolism of chloramphenicol succinate (CAPS) by human bone marrow was studied in vitro using 75 marrow samples. Whole marrow samples were incubated with CAPS with or without reduced nicotinamide adenine dinucleotide phosphate for 1, 2 and 3 h at
Roberta A Gottlieb et al.
Autophagy, 7(4), 434-435 (2010-12-29)
Interventions that reduce infarct size in animal models have largely failed to improve outcome in patients suffering acute myocardial infarction (MI), or 'heart attack'. Our group recently reported a reduction of infarct size by chloramphenicol treatment in a porcine in
A S Borde et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 80(3), 630-637 (2011-12-14)
The aim of this study was to determine the stability of three ester prodrugs, chloramphenicol succinate, enalapril and candesartan cilexetil, in human proximal small intestinal fluid (HIF), dog proximal small intestinal fluids (DIF) and simulated intestinal fluid (FaSSIF), with the
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej